NEW YORK (GenomeWeb) – IsoPlexis announced today that it has raised $13.5 million in a Series B financing round.
The round was led by Spring Mountain Capital, and included Connecticut Innovations, North Sound Ventures, and Ironwood Capital. IsoPlexis said that it would use the funds to continue product development and marketing.
IsoPlexis has developed a system — called IsoCode — that captures full omic function from thousands of single cells in parallel, as well as a cell-mapping platform — called IsoLight — that characterizes differences among single cells to reveal full functional profiles and polyfunctionality among cell subsets. The company markets the technologies for use in understanding patient responses to immunotherapies such as CAR-T.
“This latest funding round allows us to continue our work to advance the fight against cancer,” IsoPlexis Cofounder and CEO Sean Mackay said in a statement. “Using the IsoPlexis technology, our partners are beginning to gather data to help improve future treatments for the patients with the highest need. This new funding will help us build on our momentum.”